Preclinical antitumor activity of Ferulasong A from Ferula songarica against gastric cancer: multi-omics profiling and computational assessment of a putative interaction with MDM2
This study demonstrates that Ferulasong A, a sesquiterpenoid from *Ferula songarica*, exerts potent anti-gastric cancer effects both in vitro and in vivo by suppressing tumor growth and modulating the MDM2/p53 pathway, with computational evidence suggesting a potential direct interaction between Ferulasong A and MDM2.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Gastric cancer, often called stomach cancer, remains one of the most common and deadly diseases worldwide. While doctors have many tools to fight it, including surgery and drugs, the disease often returns or becomes resistant to treatment, leaving patients with few options. In the search for new ways to fight this illness, scientists frequently look to nature. Plants have long provided the raw materials for modern medicine, offering complex chemical structures that can interfere with how cancer cells grow, divide, and spread. One such plant is Ferula songarica, a species native to the mountains of Xinjiang, China, which has been used in traditional medicine for centuries. Within this plant, researchers have isolated a specific chemical compound called Ferulasong A. While early tests showed this compound could harm cancer cells in a dish, scientists did not know exactly how it worked, whether it could stop tumors in living animals, or what specific molecular switches it might be flipping inside the body.
A team of researchers from Xinjiang Medical University and the General Hospital of the Xinjiang Military Command set out to answer these questions. They took the pure chemical compound, Ferulasong A, and tested it against two different types of human stomach cancer cells in the laboratory. They watched closely to see if the compound could stop the cells from growing, dividing, or moving. They found that the compound was effective at slowing down the cancer cells. When they treated the cells with the substance, the cells stopped making new DNA, which is the blueprint they need to copy themselves. The cells also lost their ability to form large colonies, a sign that they could no longer multiply indefinitely. Furthermore, the treatment made the cancer cells more likely to die naturally, a process known as apoptosis, and it stopped them from moving across surfaces or invading through barriers, which are the first steps cancer takes to spread to other parts of the body.
To understand how this happened, the scientists looked inside the cells to see which genes were turned on or off. They used advanced sequencing technology to read the genetic instructions of the treated cells and compared them to untreated ones. They also analyzed the tiny chemical molecules, or metabolites, inside the cells to see how their energy production and chemical processes had changed. The results showed a massive shift in the cell's internal environment. The treatment altered the way the cells processed energy and built new materials. Among the many changes, the researchers noticed a specific pattern involving two key proteins: one called MDM2 and another called p53. In healthy cells, p53 acts as a guardian that stops cancer from forming, but cancer cells often produce too much MDM2, which acts like a lock that disables p53. The researchers found that Ferulasong A reduced the amount of MDM2 and increased the amount of p53, effectively unlocking the cell's natural defense system.
The team wanted to know if the compound was physically interacting with the MDM2 protein to cause this change. Since they could not see the interaction with the naked eye, they used powerful computer simulations to model how the molecules might fit together. They built a digital 3D model of the MDM2 protein and the Ferulasong A compound and ran simulations to see if they would stick together. The computer models suggested that the compound could indeed fit into a specific pocket on the MDM2 protein, forming a stable connection that would prevent MDM2 from doing its job. While this was a computer prediction and not a direct physical measurement, it provided a strong structural reason for why the protein levels changed in the lab experiments.
To see if these findings held up in a living system, the researchers grew human stomach cancer tumors in mice. They divided the mice into groups, giving some the compound and others a placebo or a standard chemotherapy drug. Over two weeks, the mice treated with Ferulasong A developed significantly smaller tumors than the untreated mice. The tumors grew more slowly, and by the end of the experiment, the tumors in the treated mice weighed much less. Importantly, the mice did not lose significant body weight, suggesting the treatment was not causing the severe side effects often seen with stronger chemotherapy drugs. When the researchers examined the tumors under a microscope, they confirmed what they had seen in the lab: the treated tumors had fewer signs of rapid cell division and showed lower levels of the MDM2 protein and higher levels of the p53 protein.
The study concludes that Ferulasong A is a promising candidate for fighting stomach cancer, capable of stopping tumor growth in both cell cultures and living animals by targeting the MDM2 and p53 pathway. However, the researchers are careful to note that while the computer models suggest the compound binds directly to the MDM2 protein, this specific physical interaction has not yet been proven in a lab experiment. They also point out that more work is needed to see if this effect holds true in other types of cancer or in different patient models. For now, the study provides a clear map of how this natural compound disrupts cancer cells, offering a solid foundation for future research to develop it into a potential treatment.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.